Harmanci K.Akan O.Y.Pirildar T.Ortan P.Ulman C.2024-07-222024-07-22201802780240http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15131Background. There is no specific marker that shows the disease activity in Behçet’s disease. Aim. In this study, we aimed to investigate VEGF-B and VEGF gene expressions and sTREM-1 levels in association with the activation of Behçet’s disease. Study Design. Case-control study. Methods. Clinical features of patients who applied in the rheumatology clinic and were diagnosed with BD according to the international working group’s criteria were investigated. 30 healthy volunteers and 30 patients in the active period according to the EBDCAF scoring were studied. VEGF-B and VEGF gene expressions and sTREM-1 levels were studied in the serum samples of the patients and the control subjects. Results. The VEGF-B expressions and sTREM-1 levels were higher in the BD than those in the healthy group, but this difference did not reach statistical significance. VEGF gene expression was statistically significant (p = 0 008). Behçet’s disease patients with oral aphthae, genital ulcer, eye, joint, vascular, skin, and neurological involvement were analyzed separately as subgroups. We find that VEGF gene expression level of Behçet’s disease patients with joint involvement (arthritis/arthralgia) and also VEGF-B and VEGF gene expression of Behçet’s disease with vascular involvement (DVT/thrombophlebitis) were significantly higher (p = 0 035, p = 0 021). Each subgroup was analyzed with the control group. We determined that VEGF gene expression in all subgroups was significantly higher than that in the control group. At the same time, VEGF-B levels of patients with genital ulcer and vascular involvement (DVT/thrombophlebitis) were significantly higher than those in the control group. Conclusion. VEGF-B and VEGF gene expressions can be activity indicators for BD. In addition, this study shows that new treatment options should be explored for Behçet’s disease patients with joint and vascular involvement. In the following years, new treatment methods are needed to investigate for revealing the role of the etiopathogenesis of BD and the activation and prognosis of VEGF by examining this study and providing much more participation. In our study group, the sTREM-1 levels were high but the results did not reach statistical significance. More studies are needed with larger groups in order the highlight the exact role of STREM-1 in Behçet’s disease. Copyright © 2018 Kadir Harmanci et al. This is an open access article distributed under the Creative Commons Attribution LicenseEnglishAll Open Access; Gold Open Access; Green Open AccessAdultBehcet SyndromeBiomarkers, TumorCase-Control StudiesFemaleGene Expression RegulationHumansMaleMiddle AgedTriggering Receptor Expressed on Myeloid Cells-1Up-RegulationVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Btriggering receptor expressed on myeloid cells 1vasculotropinvasculotropin BTREM1 protein, humantriggering receptor expressed on myeloid cells 1tumor markervasculotropin Avasculotropin BVEGFA protein, humanVEGFB protein, humanadultarthralgiaarthritisarthropathyArticleBehcet diseaseclinical articleclinical evaluationclinical featurecontrolled studycorrelation analysisdeep vein thrombosisdisease activityEBDCAF scoreenzyme linked immunosorbent assayeye diseasefemalegene expression levelgenital ulcerhumanlimit of detectionmalemouth ulcerneurologic diseasepathogenesisprognosisprotein expressionscoring systemskin diseasestatistical significancethrombophlebitisBehcet diseasebloodcase control studygene expression regulationgeneticsmiddle agedupregulationArticle10.1155/2018/2649392